Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom

Rhea-AI Summary

Nuvation Bio (NYSE: NUVB) announced that the UK MHRA has validated the Marketing Authorisation Application for taletrectinib to treat advanced ROS1-positive non-small cell lung cancer (NSCLC). The MAA, filed via the International Recognition Procedure, will now undergo full review.

The submission is based on pivotal Phase 2 TRUST-I and TRUST-II data. A separate MAA is under review by the European Medicines Agency, and additional filings are planned for Canada and other Eisai-licensed regions. Taletrectinib already has approvals for ROS1+ NSCLC in the US, Japan and China.

AI-generated analysis. Not financial advice.

Positive

• MHRA validates UK Marketing Authorisation Application for taletrectinib in ROS1+ NSCLC
• EMA Marketing Authorisation Application for taletrectinib validated in March 2026
• Regulatory submissions supported by pivotal Phase 2 TRUST-I and TRUST-II study data
• Taletrectinib already fully approved for ROS1+ NSCLC in the US
• Taletrectinib approved for advanced ROS1+ NSCLC in Japan and China
• Exclusive Eisai collaboration covers Europe and multiple additional international territories

Negative

• UK MHRA still must decide whether to approve or reject taletrectinib
• Regulatory reviews in Europe, the UK and planned regions remain pending completion

News Market Reaction – NUVB

-0.71%

8 alerts

-0.71% News Effect

-$15M Valuation Impact

$2.07B Market Cap

0.5x Rel. Volume

On the day this news was published, NUVB declined 0.71%, reflecting a mild negative market reaction. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $15M from the company's valuation, bringing the market cap to $2.07B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Annual lung cancer cases (U.K.): 50,200 cases per year NSCLC share of lung cancer: 80–85% ROS1+ mutation rate: 2% of NSCLC patients +5 more

8 metrics

Annual lung cancer cases (U.K.) 50,200 cases per year Incidence of lung cancer in the United Kingdom

NSCLC share of lung cancer 80–85% Proportion of lung cancers that are NSCLC in the U.K.

ROS1+ mutation rate 2% of NSCLC patients Share of NSCLC patients with ROS1-positive tumors

Pivotal studies 2 Phase 2 trials TRUST-I and TRUST-II programs supporting taletrectinib MAA

Convertible notes offering size $250,000,000 0.75% Convertible Senior Notes due 2032 (424B5 filed June 26, 2026)

Convertible notes coupon 0.75% per year Interest rate on 2032 Convertible Senior Notes

Initial conversion price $7.84 per share Based on 127.4941 shares per $1,000 principal amount

Expected net proceeds $241.2 million Net proceeds from 0.75% Convertible Senior Notes due 2032

Peers on Argus

NUVB traded lower while only one tracked peer, ZYME, also appeared in momentum d...

1 Down

NUVB traded lower while only one tracked peer, ZYME, also appeared in momentum data moving down. With fewer than two peers moving in the same direction, the weakness screens as stock-specific rather than a broad biotech rotation.

Historical Context

5 past events · Latest: Jun 25 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jun 25	Convertible notes offering	Negative	-10.1%	Convertible senior notes deal that raised leverage and potential equity dilution.
May 27	Conference presentation	Neutral	+0.2%	Jefferies conference participation update with no new clinical or financial data.
May 27	Clinical QoL data	Positive	+1.1%	Phase 2 TRUST-II quality-of-life data showing most patients maintained or improved status.
May 13	Manufacturing collaboration	Positive	-1.3%	Thermo Fisher collaboration to secure U.S.-based IBTROZI manufacturing capacity.
May 06	Regulatory sNDA update	Positive	+4.3%	FDA acceptance of IBTROZI sNDA with long mDOR and mPFS data in ROS1+ NSCLC.

Pattern Detected

NUVB has generally reacted in line with the tone of prior clinical and corporate updates, with only occasional divergence on partnership/manufacturing news.

Regulatory & Risk Context

Short Interest: 18.94%

Short Interest

18.94% of float

0% 15% 30%+

moderate as of 2026-05-29 Days to cover: 14.35

Short interest appears elevated, suggesting susceptibility to sharper moves and potential squeeze dynamics if sentiment or liquidity shifts abruptly.

Market Pulse Summary

This announcement highlights MHRA validation of the taletrectinib MAA, extending prior EMA progress ...

Analysis

This announcement highlights MHRA validation of the taletrectinib MAA, extending prior EMA progress and supported by Phase 2 TRUST data. Investors may weigh this against recent convertible note financing and net insider selling when tracking future regulatory milestones.

Key Terms

marketing authorisation application, international recognition procedure, phase 2, non-small cell lung cancer

4 terms

marketing authorisation application regulatory

"has validated the Marketing Authorisation Application (MAA) submitted by its partner"

A marketing authorisation application is the formal package a drug or medical-device maker submits to a health regulator to get permission to sell a product. Think of it as an application for a sales license: regulators review safety, effectiveness and manufacturing quality before granting permission. Investors watch these submissions because approval unlocks revenue and reduces development risk, while rejection or delays can materially affect a company’s value and timeline.

international recognition procedure regulatory

"The application was submitted through the International Recognition Procedure, which"

An international recognition procedure is the formal process by which one country or regulatory body accepts approvals, certifications, or decisions made by another, allowing a product, clinical result, or legal status to be used across borders without repeating the full review. For investors it matters because recognition can speed market entry, cut costs and lower regulatory risk—like a passport shortcut that lets a product reach more customers faster and with less uncertainty.

phase 2 medical

"two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, evaluating taletrectinib"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

non-small cell lung cancer medical

"for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

FOR U.S. AUDIENCES ONLY. THIS PRESS RELEASE IS NOT FOR A U.K. AUDIENCE.

A Marketing Authorisation Application with the European Medicines Agency is also under regulatory review for approval

NEW YORK, June 29, 2026 /PRNewswire/ -- Nuvation Bio (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has validated the Marketing Authorisation Application (MAA) submitted by its partner Eisai Co, Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), for taletrectinib for the treatment of advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). The application was submitted through the International Recognition Procedure, which takes into account approvals from trusted regulatory partners and supports expedited access to medicines in the U.K. The application will now be evaluated by the MHRA to decide whether to approve or reject the application.

In January 2026, Eisai and Nuvation Bio announced they had entered into an exclusive licensing and collaboration agreement in Europe and additional countries* outside the U.S., China and Japan to extend the global reach of taletrectinib. Taletrectinib is an oral treatment for patients living with advanced ROS1+ NSCLC (marketed as IBTROZI^® in the U.S. and Japan). In March 2026, the European Medicines Agency validated the MAA for taletrectinib. Additional filings are planned for Canada and other regions included in Eisai's licensed territories.

Within the U.K., there are around 50,200 new lung cancer cases every year. Around 80 to 85% of all lung cancers are NSCLC, of which approximately 2% of patients harbor the ROS1+ mutation.

The application is based on data from the two pivotal Phase 2 clinical studies, TRUST-I and TRUST-II, evaluating taletrectinib in patients globally. Results from a pooled analysis of the TRUST clinical program were originally published in the Journal of Clinical Oncology in April 2025, and updated data reflecting longer patient follow-up were presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, further building the efficacy and safety profile observed to date. Updated results from the TRUST-I study were also simultaneously published in April 2026 in the Journal of Clinical Oncology.

"We are pleased to see taletrectinib advance into the regulatory review process in the U.K. following the recent progress with the EMA," said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. "Having seen the meaningful impact taletrectinib has already brought to patients in the U.S., China and Japan, we are excited about this important step in expanding access to this medicine. This validation brings us closer to delivering taletrectinib to patients in the U.K. and reinforces our commitment to making it available to patients around the world."

In June 2025, the U.S. Food and Drug Administration (FDA) granted full approval to taletrectinib for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy, following a Priority Review and double Breakthrough Therapy designations. Taletrectinib is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON^®.

* Eisai's licensed territories: Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India

About ROS1+ NSCLC
Each year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.

About Taletrectinib
Taletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naive and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com.

About the TRUST Clinical Program
The TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of taletrectinib. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating taletrectinib for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating taletrectinib for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating taletrectinib versus crizotinib in 194 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs. 

About the International Recognition Procedure (IRP) in the United Kingdom
IRP is a regulatory pathway established by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) that allows the agency to take into account the expertise and decision-making of trusted international reference regulators, such as the European Medicines Agency (EMA) and FDA.

Under IRP, MHRA conducts a targeted assessment based on existing regulatory evaluations, with the aim of supporting patients in the U.K. with expedited access to safe and effective medicines.

About Nuvation Bio
Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients' lives. Our diverse pipeline includes taletrectinib (IBTROZI^®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; and an innovative drug-drug conjugate (DDC) program. 

Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc). 

U.S. Indication
IBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC).

U.S. IMPORTANT SAFETY INFORMATION FOR IBTROZI^® (taletrectinib)

WARNINGS AND PRECAUTIONS

Hepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).

Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.

Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.

Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).

ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.

QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.

In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.

Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.

Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.

Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).

Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.

Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.

Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.

ADVERSE REACTIONS

Among patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%).

The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%).

DRUG INTERACTIONS

• Strong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant use.
• Gastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI.

OTHER CONSIDERATIONS

• Pregnancy: Please see important information in Warnings and Precautions under Embryo-Fetal Toxicity.
• Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.
• Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.
• Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.
• Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation.

Please see accompanying full U.S. Prescribing Information.

Forward-Looking Statements of Nuvation Bio Inc.

Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Eisai's plans to file for regulatory approval of taletrectinib in Canada and other regions included in Eisai's licensed territories, the European Medicines Agency's consideration of full approval for the MAA, and taletrectinib's therapeutic potential, the clinical objectives when considering treatment options for advanced ROS1+ NSCLC and IBTROZI'S therapeutic potential. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward-looking statements, including but not limited to the challenges associated with the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on May 4, 2026 under the heading "Risk Factors," and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

Nuvation Bio Investor Contact
JR DeVita
ir@nuvationbio.com 

Nuvation Bio Media Contact
Kaitlyn Nealy
media@nuvationbio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvation-bio-announces-marketing-authorisation-application-for-taletrectinib-for-the-treatment-of-advanced-ros1-positive-non-small-cell-lung-cancer-validated-in-the-united-kingdom-302813162.html

SOURCE Nuvation Bio Inc.

FAQ

What did Nuvation Bio (NYSE: NUVB) announce about taletrectinib in the UK on June 29, 2026?

Nuvation Bio announced that the UK MHRA validated the Marketing Authorisation Application for taletrectinib in advanced ROS1-positive NSCLC. According to Nuvation Bio, the application will now be formally evaluated under the International Recognition Procedure for a potential UK approval decision.

What is taletrectinib and which lung cancer patients could it treat if approved in the UK?

Taletrectinib is an oral treatment candidate for patients with advanced ROS1-positive non-small cell lung cancer. According to Nuvation Bio, ROS1 mutations occur in about 2% of NSCLC cases, a subset within the roughly 80–85% of lung cancers classified as NSCLC in the UK.

What clinical data support the MHRA and EMA applications for taletrectinib in ROS1-positive NSCLC?

The MHRA and EMA applications are based on two pivotal Phase 2 TRUST-I and TRUST-II studies. According to Nuvation Bio, pooled TRUST results were published in 2025, with updated efficacy and safety data presented in April 2026 and in a concurrent Journal of Clinical Oncology publication.

Is taletrectinib (NUVB) already approved for ROS1-positive NSCLC in other countries?

Yes, taletrectinib is already approved for ROS1-positive NSCLC in the US, Japan and China. According to Nuvation Bio, the US FDA granted full approval in June 2025, and the drug is marketed as IBTROZI in the US and Japan and as DOVBLERON in China.

How does the MHRA International Recognition Procedure affect taletrectinib’s review in the UK?

The International Recognition Procedure allows the MHRA to consider approvals from trusted regulatory partners when reviewing taletrectinib. According to Nuvation Bio, this pathway is intended to support expedited access to medicines in the UK but still requires a formal approve-or-reject decision.

What regions are covered by Eisai’s licensing and collaboration agreement for taletrectinib with Nuvation Bio?

Eisai holds exclusive taletrectinib rights in Europe and additional territories outside the US, China and Japan. According to Nuvation Bio, the licensed regions include Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand and several Asia-Pacific countries.

What does the EMA Marketing Authorisation Application mean for NUVB investors following the UK MHRA validation?

The EMA has already validated a separate Marketing Authorisation Application for taletrectinib in March 2026. According to Nuvation Bio, combined EMA and MHRA reviews, plus planned filings in Canada and other territories, expand taletrectinib’s potential global reach beyond currently approved US, Japanese and Chinese markets.